Biogen (NASDAQ:BIIB) Issues FY 2025 Earnings Guidance

Biogen (NASDAQ:BIIB) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 15.250-16.250 for the period, compared to the consensus EPS estimate of 16.240. The company issued revenue guidance of -.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Jefferies Financial Group downgraded Biogen from a “buy” rating to a “hold” rating and dropped their target price for the stock from $250.00 to $180.00 in a report on Monday, December 9th. TD Cowen dropped their target price on Biogen from $300.00 to $275.00 and set a “buy” rating for the company in a report on Thursday, October 31st. Needham & Company LLC downgraded Biogen from a “buy” rating to a “hold” rating and set a $270.00 target price for the company. in a report on Monday, November 18th. Wells Fargo & Company decreased their price target on Biogen from $190.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Finally, Mizuho decreased their price target on Biogen from $251.00 to $207.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. Seventeen research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $221.65.

Biogen Stock Down 2.2 %

Shares of NASDAQ:BIIB opened at $139.39 on Wednesday. The company has a market capitalization of $20.31 billion, a PE ratio of 12.59, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The business has a fifty day moving average price of $148.71 and a two-hundred day moving average price of $174.84. Biogen has a 1 year low of $138.72 and a 1 year high of $244.95.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.